Duvelisib | IPI-145 | PI3Kδ Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / PI3K / Duvelisib

Duvelisib {[allProObj[0].p_purity_real_show]}

货号：A270608 同义名： IPI-145;INK1197

Duvelisib is a selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.

Duvelisib 化学结构
CAS号：1201438-56-3

Duvelisib 3D分子结构
CAS号：1201438-56-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Duvelisib 纯度/质量文件产品仅供科研

货号：A270608 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

PI3K 亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	98%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	98%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					98+%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				mTOR,DNA-PK	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						98%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	99%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			mTOR,DNA-PK	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			mTOR,DNA-PK	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				98%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	99+%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				98+%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	99%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			mTOR,DNA-PK	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			Src,Sirtuin,PKC	97%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						98%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					98%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				95+%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				99+%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				98%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				98%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		DNA-PK,MLCK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		PTEN,Akt	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		CDK,ATM/ATR,Akt	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		mTOR,DNA-PK	99%+
Cinobufagine						✔		Akt	98%
α-Linolenic acid						✔			97% GC
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	97%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Duvelisib 生物活性

靶点	p110γ PI3Kγ, Ki:243 pM p110β PI3Kβ, Ki:1564 pM p110δ PI3Kδ, Ki:23 pM
描述	PI3Ks are lipid kinases participating in several cellular process. There are eight PI3 kinases have been identified as classes IA, 1B, II, and III based on the sequence homology and substrate preference. Among them, class IA PI3K is composed of a heterodimer consisting of a 110 kDa catalytic subunit (p110α, p110β and p110δ) and an 85 kDa regulatory subunit ^[2]. Duvelisib, also called IPI-145 or INK1197, is an oral and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/240 pM and 2.5nM/27nM, respectively, and is less potent to PI3K-α and PI3K-β with Ki and IC50 of 25.9nM/1.56nM and 1602nM/85nM (by recombinant PI3K isoforms), respectively. Through inhibition of PI3K-δand PI3K-γ function, Duvelisib can decrease pS473-Akt in RAJI/RAW 264.7/SKOV-3 cells as well as inhibit the proliferation of Primary B/T cells, PI3K-δ-speciﬁc degranulation of basophils and the activated GPIIb/IIIa in platelets. In animal study, Duvelisib is used in inﬂammatory, autoimmune and hematologic diseases model. For example, 10 mg/kg treatment of IPI-145 can suppress cellular inﬂammation in an OVA-induced asthma rat model with signiﬁcant suppression of TNF-a, KC/GRO, interleukin-13 (IL-13) and IL-5 levels in bronchoalveolar lavage ^[1], and also effective in a murine xenograft model of CLL^[3]. Up to now, Duvelisib is FDA approved for use in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) and follicular lymphoma ^[4].
作用机制	IPI-145 is an ATP-competitive inhibitor. ^[1]

Duvelisib 动物研究

Dose	Mice: min = 10 mg/kg^[4], max = 50 mg/kg bid^[5]
Administration	p.o.

Duvelisib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02158091	Chronic Lymphocytic Leukemia	Phase 1 Phase 2	Active, not recruiting	July 2021	United States, Massachusetts ... 展开 >> Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01925911	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> PRA International Lenexa, Kansas, United States, 66219 收起 <<
NCT03757000	B-cell Lymphoma Recurrent ... 展开 >> B-cell Chronic Lymphocytic Leukemia 收起 <<	Phase 1	Recruiting	May 30, 2019	China, Beijing ... 展开 >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD 86 10-88140650 songyuqin622@163.com Contact: Meifeng Tu, MD,PhD 86 10-88121122 44329472@qq.com Principal Investigator: Yuqin Song, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD Sub-Investigator: Lingyan Ping, MD,PhD China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD 86 25-83714511 lijianyonglm@126.com Contact: Wei Xu, MD,PhD 86 25-83714511 xuwei0484@jsph.org.cn Principal Investigator: Jianyong Li, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD 86 22-23909172 qiulg@ihcams.ac.cn Contact: Junyuan Qi, MD,PhD 86 22-23909999 qijy@ihcams.ac.cn Principal Investigator: Lugui Qiu, MD,PhD Sub-Investigator: Junyuan Qi, MD,PhD 收起 <<

Duvelisib 参考文献

[1]Winkler DG, Faia KL, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364-74

[2]Zhao HF, Wang J, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017 Jun 7;16(1):100.

[3]Winkler DG, Faia KL, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.

[4]Chen SS, Ham S, et al. Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells. Blood. vol. 126 no. 23 1753.

[5]Vangapandu HV, Jain N, et al. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May;26(5):625-632.

Duvelisib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.99mL

2.40mL

1.20mL

23.99mL

4.80mL

2.40mL

Duvelisib 技术信息

CAS号	1201438-56-3
分子式	C₂₂H₁₇ClN₆O
分子量	416.863

别名	IPI-145;INK1197
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 40 mg/mL(95.95 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02158091	Chronic Lymphocytic Leukemia	Phase 1 Phase 2	Active, not recruiting	July 2021	United States, Massachusetts ... 展开 >> Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01925911	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> PRA International Lenexa, Kansas, United States, 66219 收起 <<
NCT03757000	B-cell Lymphoma Recurrent ... 展开 >> B-cell Chronic Lymphocytic Leukemia 收起 <<	Phase 1	Recruiting	May 30, 2019	China, Beijing ... 展开 >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD 86 10-88140650 songyuqin622@163.com Contact: Meifeng Tu, MD,PhD 86 10-88121122 44329472@qq.com Principal Investigator: Yuqin Song, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD Sub-Investigator: Lingyan Ping, MD,PhD China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD 86 25-83714511 lijianyonglm@126.com Contact: Wei Xu, MD,PhD 86 25-83714511 xuwei0484@jsph.org.cn Principal Investigator: Jianyong Li, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD 86 22-23909172 qiulg@ihcams.ac.cn Contact: Junyuan Qi, MD,PhD 86 22-23909999 qijy@ihcams.ac.cn Principal Investigator: Lugui Qiu, MD,PhD Sub-Investigator: Junyuan Qi, MD,PhD 收起 <<
NCT01549106	Healthy Volunteers	Phase 1	Completed	-	Netherlands ... 展开 >> PRA International Zuidlaren, Netherlands, 9470 AE 收起 <<
NCT01947777	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> PRA International, Inc Lenexa, Kansas, United States, 66219 收起 <<
NCT02158091	-		Active, not recruiting	-	-
NCT02605694	Lymphoma	Phase 2	Withdrawn(Sponsor is focusing ... 展开 >>on studies which can enable registration of duvelisib) 收起 <<	-	United States, Florida ... 展开 >> Miami, Florida, United States, 33133 收起 <<
NCT01653756	Asthma	Phase 2	Completed	-	Germany ... 展开 >> Investigational Site Berlin, Germany Investigational Site Grosshansdorf, Germany Investigational Site Wiesbaden, Germany United Kingdom Investigational Site Harrow, United Kingdom 收起 <<
NCT01851707	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT02028039	Leukemia	Phase 2	Withdrawn	-	-
NCT01836861	Healthy	Phase 1	Completed	-	Netherlands ... 展开 >> Pharmaceuticals Research Association (PRA) Zuidlaren, Netherlands 收起 <<
NCT02049515	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 3	Enrolling by invitation	June 2019	-
NCT02204982	Follicular Lymphoma	Phase 3	Terminated(Sponsor is focusing... 展开 >> on studies which can enable registration of duvelisib) 收起 <<	-	Australia, Victoria ... 展开 >> Frankston, Victoria, Australia, 3199 France Bordeaux, France, 33076 Italy Bologna, Italy, 40138 Terni, Italy, 05100 Poland Gdynia, Poland, 81-519 收起 <<
NCT01871675	Lymphoma Chro... 展开 >>nic Lymphocytic Leukemia Non-Hodgkin Lymphoma T-cell Lymphoma 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> The Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Oklahoma Oklahoma University Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37203 收起 <<
NCT02004522	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 3	Active, not recruiting	June 2021	-
NCT01476657	Hematologic Malignancies	Phase 1	Terminated(The scope of the pr... 展开 >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) 收起 <<	-	United States, New York ... 展开 >> New York, New York, United States, 10065 United States, Ohio Columbus, Ohio, United States, 43210 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas Houston, Texas, United States, 77030 收起 <<
NCT02292225	Lymphocytic Leukemia, Chronic ... 展开 >> Lymphoma, Small Lymphocytic 收起 <<	Phase 1	Terminated(The scope of the pr... 展开 >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) 收起 <<	-	United States, California ... 展开 >> La Jolla, California, United States, 92093 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York New Hyde Park, New York, United States, 11042 United States, Ohio Columbus, Ohio, United States, 43210 United States, Texas Houston, Texas, United States, 77030 Canada, Quebec Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT02307461	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> Lenexa, Kansas, United States, 66219 收起 <<
NCT02391545	CD20+ Follicular Lymphoma	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Los Angeles, California, United States, 90095 Palo Alto, California, United States, 94304 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York Rochester, New York, United States, 14642 United States, Texas Dallas, Texas, United States, 75246 Belgium Kortrijk, Belgium, 8000 Leuven, Belgium, 3000 Wilrijk, Belgium, 2610 France Clermont-Ferrand, France, 63003 Marseille Cedex 05, France, 13385 Pessac, France, 33600 Rouen Cedex 1, France, 76038 Tours Cedex 01, France, 37044 Italy Bologna, Italy, 40138 Varese, Italy, 21100 Spain Badalona, Barcelona, Spain, 8916 Barcelona, Spain, 8097 Madrid, Spain, 28222 Salamanca, Spain, 37007 United Kingdom Leeds, United Kingdom, LS9 7TF London, United Kingdom, NW1 1BU 收起 <<
NCT02576275	Indolent Non-Hodgkin's Lymphom... 展开 >>a Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma 收起 <<	Phase 3	Withdrawn(The scope of the pro... 展开 >>gram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) 收起 <<	-	United States, Connecticut ... 展开 >> Plainville, Connecticut, United States, 06062 United States, Florida Plantation, Florida, United States, 33322 United States, Georgia Thomasville, Georgia, United States, 31792 United States, New York East Setauket, New York, United States, 11733-3456 United States, Tennessee Cookeville, Tennessee, United States, 38501 Knoxville, Tennessee, United States, 37909 United States, Washington Spokane, Washington, United States, 99208 收起 <<
NCT02640833	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma Non-Hodgkin Lymphoma 收起 <<	Phase 1	Withdrawn(Study Stopped)	February 2021	United States, Arizona ... 展开 >> Site Reference ID/Investigator# 145677 Tucson, Arizona, United States, 85724-5024 United States, Illinois Site Reference ID/Investigator# 147922 Chicago, Illinois, United States, 60611 Site Reference ID/Investigator# 148562 Harvey, Illinois, United States, 60426 United States, Indiana Site Reference ID/Investigator# 148561 Goshen, Indiana, United States, 46526 United States, Maryland Site Reference ID/Investigator# 145674 Baltimore, Maryland, United States, 21287 United States, Massachusetts Site Reference ID/Investigator# 145145 Boston, Massachusetts, United States, 02215 United States, Michigan Site Reference ID/Investigator# 148010 Detroit, Michigan, United States, 48202 United States, Missouri Site Reference ID/Investigator# 147747 St. Louis, Missouri, United States, 63110 United States, New Hampshire Site Reference ID/Investigator# 145146 Lebanon, New Hampshire, United States, 03756 United States, South Carolina Site Reference ID/Investigator# 148559 Greenville, South Carolina, United States, 29605 收起 <<
NCT02783625	Lymphoma Rela... 展开 >>psed/Refractory T-cell Lymphomas 收起 <<	Phase 1	Recruiting	May 2019	United States, California ... 展开 >> Stanford University Medical Center Recruiting Stanford, California, United States, 94305-5408 Contact: Youn Kim, MD 650-498-6000 United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Jacobsen, MD 617-582-9086 United States, Missouri University of Washington School of Medicine in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Steven Horwitz, MD 212-639-3045 United States, New York Memorial Sloan Kettering Cancer Center @ Commack Recruiting Commack, New York, United States, 11725 Contact: Steven Horwitz, MD 212-639-3045 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Steven Horwitz, MD 212-639-3045 Contact: Alison Moskowitz, MD 212-639-4839 Principal Investigator: Steven Horwitz, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Steven Horwitz, MD 212-639-3045 收起 <<
NCT03372057	Peripheral T-cell Lymphoma	Phase 2	Recruiting	December 2021	United States, California ... 展开 >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Rosemarie Abary 626-218-8087 rabary@coh.org Principal Investigator: Jasmine Zain, MD United States, Illinois Northwestern University - Feinberg School of Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Nick Cornicelli 312-695-0706 nicholas.cornicelli@northwestern.edu Principal Investigator: Barbara Pro, MD United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Erin Jeter 617-632-6218 Erin_Jeter@DFCI.HARVARD.EDU Principal Investigator: Eric Jacobsen, MD United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kristen McDaniels, BS 314-747-1207 k.mcdaniels@wustl.edu Principal Investigator: Neha Mehta-Shah, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Nasrin Ahmed 646-449-1311 ahmedn1@mskcc.org Principal Investigator: Steven Horwitz, MD University of Rochester Recruiting Rochester, New York, United States, 14627 Contact: Yelena Lerman 585-276-8333 ylerman@urmc.rochester.edu Contact: Erin Cebula erin_cebula@urmc.rochester.edu Principal Investigator: Carla Casulo, MD United States, Ohio The Ohio State Univeristy Recruiting Columbia, Ohio, United States, 43202 Contact: Pamela Heeter 614-293-9627 pam.heeter@osumc.edu Principal Investigator: Jonathan Brammer, MD 收起 <<
NCT02095587	Hepatic Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Miami, Florida, United States, 33014 收起 <<
NCT03370185	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 2	Suspended(Reassessing corporat... 展开 >>e priorities.) 收起 <<	March 2021	United States, Arizona ... 展开 >> Arizona Oncology Tempe, Arizona, United States, 85284 United States, Arkansas Genesis Cancer Center Hot Springs, Arkansas, United States, 71913 United States, California Moores UC San Diego Cancer Center La Jolla, California, United States, 92093 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Michigan QUEST Research Institute Royal Oak, Michigan, United States, 48073 United States, Montana St. Vincent Frontier Cancer Center Billings, Montana, United States, 59102 United States, New Jersey Summit Medical Group Morristown, New Jersey, United States, 07932 United States, Washington Medical Oncology Associates PS, WA Spokane, Washington, United States, 99208 收起 <<
NCT03534323	Chronic Lymphocytic Leukemia	Phase 1 Phase 2	Recruiting	June 1, 2024	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Jacob Soumerai, MD 617-726-2865 jsoumerai@mgh.harvard.edu Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Jon Arnason, MD 617-667-9920 jarnason@bidmc.harvard.edu Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Karen Francoeur, RN 617-632-5849 kalowe@partners.org Principal Investigator: Mattherw S Davids, MD 收起 <<
NCT01882803	-		Active, not recruiting	-	-
NCT02711852	Hematologic Malignancy	Phase 2	Active, not recruiting	December 2020	United States, Colorado ... 展开 >> Denver, Colorado, United States, 80218 United States, Florida Sarasota, Florida, United States, 34232 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Italy Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia Terni, Umbria, Italy, 05100 收起 <<
NCT02598570	Lymphoma	Phase 1	Completed	-	Japan ... 展开 >> Site Reference ID/Investigator# 141826 Aichi, Japan Site Reference ID/Investigator# 141595 Fukuoka, Japan Site Reference ID/Investigator# 141594 Tokyo, Japan 收起 <<
NCT01882803	Indolent Non-Hodgkin Lymphoma	Phase 2	Active, not recruiting	October 20, 2021	-

Duvelisib {[allProObj[0].p_purity_real_show]}

Duvelisib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Duvelisib 质控信息

Duvelisib 生物活性

Duvelisib 动物研究

Duvelisib 临床研究

Duvelisib 参考文献

Duvelisib 实验方案

Duvelisib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

p110γ	PI3Kγ, Ki:243 pM
p110β	PI3Kβ, Ki:1564 pM
p110δ	PI3Kδ, Ki:23 pM

Duvelisib {[allProObj[0].p_purity_real_show]}

Duvelisib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Duvelisib 质控信息

Duvelisib 生物活性

Duvelisib 动物研究

Duvelisib 临床研究

Duvelisib 参考文献

Duvelisib 实验方案

Duvelisib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Duvelisib 纯度/质量文件产品仅供科研